Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico

Jayawardene, 2014, New treatments for type 2 diabetes: Cardiovascular protection beyond glucose lowering?, Heart Lung Circ., 23, 997, 10.1016/j.hlc.2014.05.007 Wilding, 2015, Managing patients with type 2 diabetes and obesity, Practitioner., 259, 25 Lovshin, 2014, Blood pressure-lowering effects of incretin-based diabetes therapies, Can J Diabetes., 38, 364, 10.1016/j.jcjd.2014.05.001 Haluzík, 2014, Balancing benefits and risks in patients receiving incretin-based therapies: Focus on cardiovascular and pancreatic side effects, Drug Saf., 37, 1003, 10.1007/s40264-014-0238-8 Dailey, 2013, Glucagon-like peptide 1 and appetite, Trends Endocrinol Metab., 24, 85, 10.1016/j.tem.2012.11.008 Meier, 2015, Contrasting Effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial, Diabetes Care., 38, 1263, 10.2337/dc14-1984 Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis, JAMA., 298, 194, 10.1001/jama.298.2.194 Liu, 2012, Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis, Diabetes Obes Metab., 14, 810, 10.1111/j.1463-1326.2012.01606.x Abdul-Ghani, 2013, Insulin vs GLP-1 analogues in poorly controlled type2 diabetic subjects on oral therapy: A meta-analysis, J Endocrinol Invest., 36, 168 Robinson, 2013, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis, BMJ Open., 3, e001986, 10.1136/bmjopen-2012-001986 Rosenstock, 2013, Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X), Diabetes Care., 36, 2945, 10.2337/dc12-2709 Kapitza, 2013, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type2 diabetes insufficiently controlled on metformin, Diabetes Obes Metab., 15, 642, 10.1111/dom.12076 Gluud, 2014, Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes, BMJ Open., 4, e005325, 10.1136/bmjopen-2014-005325 Tasyurek, 2014, Incretins: Their physiology and application in the treatment of diabetes mellitus, Diabetes Metab Res Rev., 30, 354, 10.1002/dmrr.2501 Hirshberg, 2015, Insights from cardiovascular outcome trials with novel antidiabetes agents: What have we learned? An industry perspective, Curr Diab Rep., 15, 87, 10.1007/s11892-015-0663-9 Prasad-Reddy, 2015, A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond, Drugs Context., 4, 212283, 10.7573/dic.212283 Valencia, 2015, J Med Econ, 18, 1013, 10.3111/13696998.2015.1069297